评估 Alpelisib 加氟维司群治疗日本男性和绝经后晚期乳腺癌的疗效和安全性的研究
BYL719 (Alpelisib) 联合氟维司群治疗 PIK3CA 突变激素受体 (HR) 阳性、HER2 阴性晚期乳腺癌的男性和绝经后女性的 II 期开放标签、2 部分、多中心研究在日本接受芳香化酶抑制剂 (AI) 治疗后
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast cancer harboring a PIK3CA mutation in Japan, whose disease has progressed on or after aromatase inhibitor (AI) treatment regardless of prior CDK4/6 inhibitor use.
研究概览
详细说明
This is a Phase II open-label, 2-Part, multi-center study in Japan. The study will be conducted in two parts: Part 1 (Cohort 1) includes participants regardless of prior CDK4/6 inhibitor use and is designed to determine the recommended dose (RD), evaluate the tolerability and safety of alpelisib in combination with fulvestrant. Part 2 consists of 2 cohorts (the CDK4/6 inhibitor naive participants are in Cohort 2 and the CDK4/6 inhibitor pre-treated participants are in Cohort 3) which are designed to assess the efficacy and safety of alpelisib in combination with fulvestrant, will start once the RD of alpelisib is established.
Participants will be treated until disease progression, unacceptable toxicity, death or discontinuation from the study treatment for any other reason and will be followed for survival regardless of treatment discontinuation reason (except if consent is withdrawn or participant is lost to follow up).
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Niigata、日本、951-8566
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、4668560
- Novartis Investigative Site
-
Nagoya、Aichi-ken、日本、4678602
- Novartis Investigative Site
-
Nagoya、Aichi-ken、日本、4648681
- Novartis Investigative Site
-
-
Chiba
-
Kashiwa、Chiba、日本、2778577
- Novartis Investigative Site
-
-
Kanagawa
-
Isehara、Kanagawa、日本、2591193
- Novartis Investigative Site
-
Yokohama、Kanagawa、日本、2418515
- Novartis Investigative Site
-
-
Kumamoto
-
Kumamoto、Kumamoto、日本、8608556
- Novartis Investigative Site
-
-
Miyagi
-
Sendai、Miyagi、日本、9808574
- Novartis Investigative Site
-
-
Osaka
-
Osaka、Osaka、日本、5418567
- Novartis Investigative Site
-
Osaka、Osaka、日本、5400006
- Novartis Investigative Site
-
Suita、Osaka、日本、5650871
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo Ku、Tokyo、日本、1138677
- Novartis Investigative Site
-
Koto Ku、Tokyo、日本、1358550
- Novartis Investigative Site
-
Meguro-ku、Tokyo、日本、1528902
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Japanese man or postmenopausal woman
- Participant has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory.
- Participant has identified PIK3CA mutation (as determined by a Novartis designated laboratory)
- Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory
- Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH or SISH) test is required by local laboratory testing
- Participant has measurable disease, i.e., at least one measurable lesion as per RECIST 1.1
- Participant has advanced breast cancer
- Participant has ECOG performance status 0 or 1
Exclusion Criteria:
- Participant with symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment
- Participant has received prior treatment;
- with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor for Cohort 1 and 3
- with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR, AKT inhibitor or CDK 4/6 inhibitor for Cohort 2
- Participant has a known hypersensitivity to alpelisib or fulvestrant, or to any of the excipients of alpelisib or fulvestrant
- Participant with inflammatory breast cancer at screening
- Participant is concurrently using other anti-cancer therapy
- Participant has had surgery within 14 days prior to starting study drug or has not recovered from major side effects
- Participant with an established diagnosis at screening of diabetes mellitus type I or not controlled type II (based on FPG and HbA1c)
- Participant has currently documented pneumonitis /interstitial lung disease
- History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis
- Participant with unresolved osteonecrosis of the jaw
- Participant has a history of severe cutaneous reactions
Other protocol-defined inclusion/exclusion criteria may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)
Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular). |
[Part 1] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle. If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated. [Part 2] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.
其他名称:
Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
其他名称:
|
|
实验性的:Cohort 2: CDK4/6 inhibitor naive (Part 2)
Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular). |
[Part 1] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle. If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated. [Part 2] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.
其他名称:
Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
其他名称:
|
|
实验性的:Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)
Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular). |
[Part 1] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle. If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated. [Part 2] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.
其他名称:
Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
[Part 1] The incidence of Dose Limiting Toxicities (DLTs) of alpelisib in combination with fulvestrant
大体时间:From Cycle 1 Day 1 to Cycle 2 Day 28 (Cycle = 28 days)
|
A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 2 cycles (the first 56 days) of treatment with alpelisib in combination with fulvestrant and meets any of the criteria specified in the protocol . |
From Cycle 1 Day 1 to Cycle 2 Day 28 (Cycle = 28 days)
|
|
[Part 2] Overall Response Rate (ORR) in CDK4/6 inhibitor naive participants
大体时间:Up to approximately 36 months
|
ORR is defined as the proportion of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on local investigator assessment per RECIST 1.1. |
Up to approximately 36 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
[Part 1] Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to approximately 37 months
|
Safety is determined by incidence, type, and severity of adverse events per CTCAE v4.03 criteria including changes in laboratory values, vital signs, liver assessments, renal and cardiac assessments. |
Up to approximately 37 months
|
|
[Part 1] Number of participants with dose adjustments
大体时间:Up to approximately 37 months
|
The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) and the reasons |
Up to approximately 37 months
|
|
[Part 1] Dose intensity for alpelisib and fulvestrant
大体时间:Up to approximately 37 months
|
The dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity) |
Up to approximately 37 months
|
|
[Part 1] Duration of exposure for alpelisib and fulvestrant
大体时间:Up to approximately 37 months
|
The duration of exposure (in months) to alpelisib and fulvestrant |
Up to approximately 37 months
|
|
[Part 1] Plasma concentrations of alpelisib in combination with fulvestrant
大体时间:Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle = 28 days)
|
Summary statistics of alpelisib plasma concentrations by time point and dose level |
Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle = 28 days)
|
|
[Part 2] Overall Response Rate (ORR) for CDK4/6 inhibitor pre-treated participants
大体时间:Up to approximately 36 months
|
ORR is defined as the proportion of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on local investigator assessment per RECIST 1.1. |
Up to approximately 36 months
|
|
[Part 2] Progression Free Survival (PFS)
大体时间:Up to approximately 36 months
|
PFS is defined as the time from the date of first administration of study treatment until the date of the first documented progression or death due to any cause. PFS will be assessed based on local investigator assessment per RECIST 1.1. |
Up to approximately 36 months
|
|
[Part 2] Overall Survival (OS)
大体时间:Up to approximately 60 months
|
OS is defined as the time from date of first administration of study treatment until date of death due to any cause. |
Up to approximately 60 months
|
|
[Part 2] Clinical Benefit Rate (CBR)
大体时间:Up to approximately 36 months
|
CBR is defined as the proportion of participants with a best overall response of confirmed CR, or confirmed PR, or an overall response of confirmed stable disease (SD), lasting for a duration of at least 24 weeks. CR, PR, and SD are defined based on local investigator assessment per RECIST 1.1. |
Up to approximately 36 months
|
|
[Part 2] Duration of Response (DOR)
大体时间:Up to approximately 36 months
|
DOR only applies to participants whose best overall response is CR or PR based on local investigator assessment per RECIST 1.1. The start date is the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying cancer. |
Up to approximately 36 months
|
|
[Part 2] Time to Response (TTR)
大体时间:Up to approximately 36 months
|
TTR is defined as the time from the date of first administration of study treatment until the date of the first documented response of either CR or PR, which must be subsequently confirmed (although date of initial response is used, not date of confirmation). |
Up to approximately 36 months
|
|
[Part 2] Time to definitive deterioration of Eastern Cooperative Oncology Group (ECOG) performance status
大体时间:Up to approximately 36 months
|
Time to definitive deterioration in ECOG performance status is defined as the time from the date of first administration to the date when ECOG performance status has definitively deteriorated by at least one category compared with baseline. Deterioration is considered definitive if there is no subsequent improvement in ECOG performance status back to the baseline category or above. |
Up to approximately 36 months
|
|
[Part 2] Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to approximately 37 months
|
Incidence, type, and severity of adverse events per CTCAE v4.03 criteria including changes in laboratory values, vital signs, liver assessments, renal and cardiac assessments |
Up to approximately 37 months
|
|
[Part 2] Number of participants with dose adjustments
大体时间:Up to approximately 37 months
|
The number and percentage of participants with dose interruptions and dose reductions |
Up to approximately 37 months
|
|
[Part 2] Dose intensity for alpelisib and fulvestrant
大体时间:Up to approximately 37 months
|
The dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity) |
Up to approximately 37 months
|
|
[Part 2] Duration of exposure for alpelisib and fulvestrant
大体时间:Up to approximately 37 months
|
The duration of exposure (in months) to alpelisib and fulvestrant |
Up to approximately 37 months
|
|
[Part 2] Plasma concentrations of alpelisib in combination with fulvestrant
大体时间:Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle= 28 days)
|
Summary statistics of alpelisib plasma concentrations by time point and dose level |
Cycle 1 Day 8 (pre-dose), 15 (pre-dose, post-dose 1 hour, 3 hours) and Day 1 of Cycles 2, 4, 6, 8 (pre-dose) (Cycle= 28 days)
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CBYL719C1201
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.